Results 201 to 210 of about 53,090 (292)

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Yi Han Xia, Eric McGinnis
wiley   +1 more source

Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs. [PDF]

Nat Commun
Li J, Chaurasiya S, Sun G, Cui Q, Ye P, Qin Y, Zhou T, Wang X, Fong Y, Maus MV, Shi Y.   +10 more
europepmc   +1 more source

Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Clonal hematopoiesis (CH) is increasingly recognized as a significant biological phenomenon in aging and cancer, marked by the expansion of hematopoietic stem and progenitor cells harboring somatic mutations in genes associated with myeloid neoplasms.
Wei Du, Shunsuke Koga, Guang Yang, Saar Gill, Adam Bagg   +4 more
wiley   +1 more source

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy. [PDF]

Front Immunol
Masuda Y, Kato J, Konishi T, Honda T, Maruta M, Kawasaki N, Matsumoto M, Oka K, Mori K, Nabe S, Miyazaki Y, Matsubara E, Urata S, Kinnami S, Doi Y, Takasuka Y, Yamanouchi J, Ochi T, Takenaka K.   +18 more
europepmc   +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani, Adrian Y. S. Lee, Maureen Rischmueller, Alberta Hoi   +3 more
wiley   +1 more source

CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy. [PDF]

J Neuroinflammation
Wen M, Zheng R, Zhang H, Goldberg SY, Jian Z, Gao Y, Cheng R, Wen L, Zhao Y, Kenderian SS, Shang P.   +10 more
europepmc   +1 more source

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

Immunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu, Jan Gärtig, Stephan Eiber, Stefan Moder, Raffael Thaler, Matthias Thaler, Juliane Gruen, Marlies Vornhülz, Kevin Bahner, Luana Messa, Benjamin Kühnemuth, Jennifer Müller, Konstantin Schnell, Antonia Beimert, Carolin Perleberg, Natascha Röhrle, Maximilian Martin Ludwig Knott, Linda Hammann, Vanessa Wittmann, Patrick Layritz, Moritz Rapp, Carole Bourquin, Julia Mayerle, Stefan Endres, David Anz   +24 more
wiley   +1 more source

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study. [PDF]

HLA
Zheng H, Zhao H, Zhu X, Feng J, Wei G, Han S, Huang S, Cui J, Fu S, Zhang M, Zhang Y, Shi J, Luo Y, Chang AH, Hu Y, Huang H.   +15 more
europepmc   +1 more source

Autologous CD19/CD22 Chimeric Antigen Receptor T-cells [PDF]

, 2020
openaire   +1 more source